Live feed08:21:07·150dANALYSTRatingvia QuantisnowLeerink Partners resumed coverage on Relmada Therapeutics with a new price targetByQuantisnow·Wall Street's wire, on your screen.RLMD· Relmada Therapeutics Inc.Health CareOriginal source